Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: Modelling life expectancy using radiation dosimetry
In recent randomized trials, omitting consolidative radiotherapy in early-stage Hodgkin lymphoma (ESHL) increased relapses. However, decades of follow-up are required to observe whether lower initial disease control is compensated by reduced risk of late effects. Extrapolation beyond trial follow-up...
| Prif Awduron: | , , , , , , |
|---|---|
| Fformat: | Journal article |
| Iaith: | English |
| Cyhoeddwyd: |
American Society of Hematology
2021
|